Asciminib - the new TKI developed by Novartis - Data from phase lll study (hopefully) show we can add this to our treatment options for CML, especially for those of us who are intolerant or have not responded to multiple TKI’s.
We need to see the full data from this study but it looks hopeful. For press release and further detail please see the highlighted box on our home page.
Sandy